Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG-017 alone or with nivolumab in advanced cancers
NCT04305249Phase 1Terminated
- Sponsor
- Antengene
- Start
- Aug 2020
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tizaterkib in solid tumor and hematological malignancy (2 arms), sponsored by Antengene. Primary endpoint: Adverse Events and Serious Adverse Events at 18 months. Started Aug 2020; status: terminated.
02
Drugs
tizaterkib
03
Conditions
solid tumorhematological malignancy
Beyond the preview
Go deeper on NCT04305249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04305249.